Similarly, CASZ1 downregulation has been observed in colorectal cancer, esophageal cancer, lung adenocarcinoma, and clear cell renal cell carcinoma, where it has been associated with patient prognosis and could serve as a novel prognostic marker [17–19, 75]. The gene discussed is CASZ1; the disease is esophageal cancer.